行情

KPTI

KPTI

Karyopharm
NASDAQ

实时行情|Nasdaq Last Sale

17.82
-0.27
-1.49%
盘后: 17.82 0 0.00% 17:01 04/03 EDT
开盘
17.93
昨收
18.09
最高
18.41
最低
17.34
成交量
83.87万
成交额
--
52周最高
29.61
52周最低
4.260
市值
12.93亿
市盈率(TTM)
-5.5223
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测KPTI价格均价为33.25,最高价位43.00,最低价为25.00。

EPS

KPTI 新闻

更多
  • 特朗普称如果需要保护石油产业 他会使用关税
  • 新浪美股 · 57分钟前
  • 特朗普称使用国防生产法是为了“报复”
  • 新浪美股 · 1小时前
  • 毕马威首席经济学家:冠状病毒导致的失业比大衰退时期更糟
  • 新浪美股 · 1小时前
  • 欧佩克+会议推迟 沙特与俄罗斯紧张局势升级 周一油价料将暴跌
  • 新浪美股 · 3小时前

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

KPTI 简况

Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from the Food and Drug Administration (FDA), in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Its XPOVIO is an oral SINE compound, which blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. It is also focused on developing treatments for other diseases, such as Hematologic Malignancies and Solid Tumor Malignancies.
展开

微牛提供Karyopharm Therapeutics Inc(NASDAQ-KPTI)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的KPTI股票新闻,以帮助您做出投资决策。